Etoricoxib (CAS 202409-33-4), a selective cyclooxygenase-2 (COX-2) inhibitor marketed under brand names including Arcoxia, has emerged as a critical therapeutic agent for pain management and inflammatory conditions worldwide. According to comprehensive market research, the global etoricoxib market is experiencing significant growth​ driven by increasing demand for effective pain management solutions with reduced gastrointestinal side effects compared to traditional NSAIDs. This detailed analysis provides comprehensive insights into global etoricoxib buyers, covering key purchasing countries, quality requirements, regional market dynamics, and strategic procurement approaches for 2026. 1. Global Etoricoxib Market Overview and Product Segmentation The etoricoxib market exhibits distinct characteristics based on dosage forms, application areas, and regional regulatory approvals, with different…